A new once-a-day fentanyl citrate patch (Fentos® Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.

Poor adhesion of fentanyl transdermal patches may mimic end-of-dosage failure after 48 hours and prompt early patch replacement in hospitalized cancer pain patients. J Pain Res (2016) 0.75

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain (2001) 16.05

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26

The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain (2008) 2.48

Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain (2010) 1.70

Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs (2001) 1.37

Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain (1997) 1.13

Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage (1998) 1.11

Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain. J Pain Symptom Manage (2012) 0.99

The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Support Care Cancer (2010) 0.90

Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol (2006) 0.89

Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer. Am J Hosp Palliat Care (2012) 0.86

Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol) (2011) 0.84

Managing breakthrough pain. Curr Pain Headache Rep (2011) 0.81

Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw (2013) 0.80

Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol (1998) 0.77

Treatment strategies to overcome end-of-dose failure with oral and transdermal opioids. J Pharm Pract (2011) 0.75

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage (2013) 1.00